BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29348788)

  • 21. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
    Gu X; Jia S; Wei W; Zhang WH
    Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.
    Li X; Zhou J; Huang K; Tang F; Zhou H; Wang S; Jia Y; Sun H; Ma D; Li S
    PLoS One; 2015; 10(4):e0122361. PubMed ID: 25860888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer.
    Pylväs-Eerola M; Liakka A; Puistola U; Koivunen J; Karihtala P
    Anticancer Res; 2016 Jul; 36(7):3425-31. PubMed ID: 27354603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-associated macrophages in human breast cancer parenchyma negatively correlate with lymphatic metastasis after neoadjuvant chemotherapy.
    Mitrofanova I; Zavyalova M; Telegina N; Buldakov M; Riabov V; Cherdyntseva N; Kzhyshkowska J
    Immunobiology; 2017 Jan; 222(1):101-109. PubMed ID: 27510849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.
    Volders JH; Haloua MH; Krekel NM; Negenborn VL; Barbé E; Sietses C; Jóźwiak K; Meijer S; van den Tol MP;
    Eur J Surg Oncol; 2016 Jul; 42(7):986-93. PubMed ID: 27211343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
    Patel T; Gupta A; Shah M
    J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and clinical significance of Kelch-like epichlorohydrin-associated protein 1 in breast cancer.
    Zhang L; Yang WP; Wu LY; Zhu X; Wei CY
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy with MRI monitoring for breast cancer.
    Dave RV; Millican-Slater R; Dodwell D; Horgan K; Sharma N
    Br J Surg; 2017 Aug; 104(9):1177-1187. PubMed ID: 28657689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
    Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
    Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P-glycoprotein expression as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Vishnukumar S; Umamaheswaran G; Anichavezhi D; Indumathy S; Adithan C; Srinivasan K; Kadambari D
    Indian J Cancer; 2013; 50(3):195-9. PubMed ID: 24061458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.
    König L; Kasimir-Bauer S; Hoffmann O; Bittner AK; Wagner B; Manvailer LF; Schramm S; Bankfalvi A; Giebel B; Kimmig R; Horn PA; Rebmann V
    Hum Immunol; 2016 Sep; 77(9):791-9. PubMed ID: 26796737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.
    Chintamani ; Singh JP; Mittal MK; Saxena S; Bansal A; Bhatia A; Kulshreshtha P
    World J Surg Oncol; 2005 Sep; 3():61. PubMed ID: 16164742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review.
    Parekh T; Dodwell D; Sharma N; Shaaban AM
    Pathobiology; 2015 Sep; 82(3-4):124-32. PubMed ID: 26330353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.